Cellectis Bioresearch SAS Sustainability Profile
Cellectis Bioresearch SAS, a prominent player in the biotechnology sector, is headquartered in France and operates extensively across Europe and North America. Founded in 1999, the company has established itself as a leader in gene editing and cell engineering, focusing on innovative solutions for research and therapeutic applications. Cellectis is renowned for its proprietary technologies, including TALEN® gene editing tools, which offer precision and versatility in genetic modifications. This unique approach positions Cellectis at the forefront of the bioresearch industry, catering to a diverse clientele ranging from academic institutions to pharmaceutical companies. With a commitment to advancing genetic research, Cellectis has achieved significant milestones, including collaborations with major industry partners and contributions to groundbreaking studies. Its reputation for excellence and innovation solidifies its market position as a trusted provider of cutting-edge biotechnological solutions.
DitchCarbon Score
How does Cellectis Bioresearch SAS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cellectis Bioresearch SAS's score of 32 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cellectis Bioresearch SAS's reported carbon emissions
Cellectis Bioresearch SAS, headquartered in France, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Cellectis S.A., which may influence its climate commitments and reporting practices. As of now, Cellectis Bioresearch SAS has not established any documented reduction targets or initiatives, nor does it participate in the Science Based Targets initiative (SBTi) or other climate pledges. This lack of specific commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the absence of reported emissions and reduction targets, it is essential for Cellectis Bioresearch SAS to consider implementing robust climate action plans to align with industry standards and expectations. This could include setting measurable targets for reducing greenhouse gas emissions across all scopes, particularly Scope 1 and Scope 2 emissions, which are typically within a company's direct control. In summary, while Cellectis Bioresearch SAS currently lacks specific emissions data and reduction commitments, its affiliation with Cellectis S.A. may provide a framework for future climate initiatives.
How Carbon Intensive is Cellectis Bioresearch SAS's Industry?
How Carbon Intensive is Cellectis Bioresearch SAS's Location?
Cellectis Bioresearch SAS's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cellectis Bioresearch SAS has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
